WS #12576
Holding: newest synthesis is 117d 10h old
Nurix finalizes $700M upfront collaboration with Roche for BTK degrader bexobrutideg, potential $2.3B milestones.
Nurix Therapeutics-Roche collaboration
Nurix finalizes $700M upfront collaboration with Roche for BTK degrader bexobrutideg, potential $2.3B milestones.